From SNPedia
CYP2C8 SNP, defining the CYP2C8*3 allele (along with rs11572080).
Individuals carrying this SNP may show increased risk of developing acute gastrointestinal bleeding during the use of NSAIDs that are CYP2C8 or CYP2C9 substrates, such as aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.[PMID 19422321]
| ? | (C;C) (C;T) (T;T) |
|---|
 |
| PharmGKB | PA161660769 |
| Name | CYP2C8: K399R, A1196G |
| Annotation | The variant is part of the CYP2C8*3 allele. In in vitro studies, the recombinant expressed CYP2C8*3 exhibits markedly impaired metabolism of paclitaxel and arachidonic acid. |
| Gene | CYP2C8 |
| Featue | Exon/NonSyn |
| Evidence | PubMed ID:11668219 |
| Drugs | paclitaxel |
| Diseases | |
| Curation Level | Curated |
